Retension Pharmaceuticals adopts amended and restated bylaws ahead of IPO close
Retension Pharmaceuticals adopted amended and restated bylaws that took effect immediately before its IPO closing on Oct. 13, 2026. The updated bylaws had been authorized by the board and stockholders ahead of the offering. A third amended and restated certificate of incorporation was filed in Delaware on Oct. 9, 2026,